Targets › GJA1
1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology.
Structural component of the gap junction, a specialized intercellular structure consisting of a cluster of closely packed pairs of transmembrane channels, the connexons, that allow passage of small molecules and electrical signals between neighboring cells (By similarity). Forms homotypic and heterotypic channels gated by transjunctional voltage (By similarity). (UniProt, P17302)
Open in Phaseline: the race on GJA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Glaukos | lufepirsen connexin43 antisense oligonucleotide | GJA1 | Phase 2 | Persistent Corneal Epithelial Defect | – |
Persistent Corneal Epithelial Defect (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.